[Effects of mercazolyl and L-thyroxine on the antiedematous activity of immunotropic preparations during development of toxic brain edema and swelling].
Platonov. I A IA; Anashchenkova. T A TA; Andreeva. T A TA
Key Findings
- Thyroid hypo‑ or hyper‑function alters the brain‑edema‑reducing effect of immune peptides.
- Combining mercazolyl or L‑thyroxine with thymogen, thymalin, and cycloferon reduced brain tissue density compared to untreated rats.
- L‑thyroxine alone increased water content in brain tissue, suggesting it may worsen edema under certain conditions.
Practical Outcomes
- For most biohackers, the findings offer little direct guidance. The study suggests thyroid status could influence how immune‑modulating peptides affect brain swelling, but it’s an animal experiment with no clear human protocol. Until human data emerge, there’s no actionable dosage or regimen to adopt.
Summary
In rats, messing with thyroid hormones changes how immune‑boosting peptides like thymogen work against brain swelling. Adding thyroid drugs with thymogen and similar peptides lowered brain water content, but the overall effect was modest and the study was done in a very specific animal model of toxic brain edema.
Abstract
Dysfunction of thyroid gland plays an important role in the pathogenesis of brain edema and swelling. Toxic brain edema and swelling was modeled under condition of hypo- and hyperfunction of thyroid gland. Mercazolyl and L-thyroxine ambiguously influence the development of toxic brain edema and swelling in rats. L-thyroxin (35.7 microg/kg) favors increase in the water content in brain tissue, which can be considered as synergism with the edematous factor and the formation of brain tissue susceptibility to the development of brain edema and swelling. The administration of mercazolyl (5 mg/kg) and L-thyroxin (35.7 microg/kg) with thymogen (10 microg/kg), thymalin (1.2 mg/kg), cycloferon (0.5 mg/kg) results in decreasing brain tissue density as compared to intact animals. Dysfunction of the thyroid gland leads to changes in pharmacodynamics of immune preparations, which results in a decrease of their antiedematous activity.
Study Information
pubmed
2008